MYC Therapeutics is a biotechnology company focused on developing therapies that target the MYC oncogene, a key driver in numerous aggressive cancers. The company's research and development efforts are centered on creating novel treatments that address this challenging molecular target. Their work aims to provide new therapeutic options for patients with MYC-driven malignancies.
Funding
Funding not disclosed
Founders
Product
Problem
Cancers driven by the MYC oncogene, including many aggressive solid tumors and hematological malignancies, remain difficult to treat due to the protein's complex structure and its role in fundamental cellular processes. Existing therapeutic approaches have struggled to effectively and safely target MYC, leaving a significant unmet need for patients with these high-risk cancers.
Solution
MYC Therapeutics is a biotechnology company dedicated to developing innovative therapies that directly target the MYC oncogene. The company is advancing a pipeline of drug candidates designed to inhibit MYC function through distinct mechanisms, aiming to disrupt tumor growth and survival. By focusing specifically on this challenging target, MYC Therapeutics seeks to create treatments that are both effective and selective for cancer cells, potentially offering a new standard of care for patients with MYC-driven tumors.
Target Audience
The primary audience includes oncologists and clinical researchers specializing in cancers with MYC amplification or overexpression, as well as patients with these difficult-to-treat malignancies.
Features
- Pipeline of novel therapeutic candidates specifically designed to target the MYC oncogene
- Research programs exploring multiple mechanisms to inhibit MYC activity
- Focus on developing treatments for a range of MYC-driven cancers, including solid tumors and hematological malignancies
- Proprietary drug development platform aimed at overcoming the historical challenges of targeting MYC